Home » Topics » BioWorld Science

BioWorld Science
RSS

Dystrophy mutation protects cells from HIV infection

Sep. 6, 2019

ADC traffic rules revealed

Sep. 6, 2019

New trials evaluate IPI-549 in combination therapies for solid tumors

Sep. 5, 2019

Gilead Sciences initiates phase Ib/II study of GS-4224 in advanced solid tumors

Sep. 5, 2019

CellCentric initiates phase I/IIa study of CCS-1477 in hematological malignancies

Sep. 5, 2019

Applied Therapeutics begins phase III study of AT-1001 for diabetic cardiomyopathy

Sep. 5, 2019

European Commission approves Stelara for moderate to severely active ulcerative colitis

Sep. 5, 2019

Tonix begins phase I study of TNX-601 for daytime treatment of PTSD

Sep. 5, 2019

First safety data presented from phase II trial of revacept

Sep. 5, 2019

Idera Pharmaceuticals and Abbvie to collaborate on immunooncology trial

Sep. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...